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Background: Chemokines have been implicated in tumor progression and metastasis. In melanoma, chemokine
receptors have been implicated in organ selective metastasis by regulating processes such as chemoattraction,
adhesion and survival.
Methods: In this study we have analyzed, using flow cytometry, the systems formed by the chemokine receptors
CXCR3, CXCR4, CXCR7, CCR7 and CCR10 and their ligands in thirteen human melanoma cell lines (five established
from primary tumors and eight established from metastasis from different tissues). WM-115 and WM-266.4
melanoma cell lines (obtained from a primary and a metastatic melanoma respectively) were xenografted in
nude mice and the tumors and cell lines derived from them were also analyzed.
Results: Our results show that the melanoma cell lines do not express or express in a low degree the chemokine
receptors on their cell surface. However, melanoma cell lines show intracellular expression of all the aforementioned
receptors and most of their respective ligands. When analyzing the xenografts and the cell lines obtained from them
we found variations in the intracellular expression of chemokines and chemokine receptors that differed between the
primary and metastatic cell lines. However, as well as in the original cell lines, minute or no expression of the
chemokine receptors was observed at the cell surface.
Conclusions: Coexpression of chemokine receptors and their ligands was found in human melanoma cell lines.
However, this expression is intracellular and receptors are not found at the cell membrane nor chemokines are
secreted to the cell medium. The levels of expressed chemokine receptors and their ligands show dynamic variations
after xenotransplantation that differ depending on the origin of the cell line (from primary tumor or
from metastasis).
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Table 1 Cell lines
Tumor Cell line Origin Source
Melanoma
IPC-298 Primary DSMZ
Mel-Juso Primary DSMZ
Mel-HO Primary DSMZ
IGR-39 Primary DSMZ
WM-115 Primary ECACC
A-375 Skin metastasis ATCC
MeWo Lymph node metastasis ATCC
SK-Mel28 Skin metastasis ATCC
Malme-3 M Lung metastasis ATCC
SK-Mel 2 Skin metastasis ATCC
WM-266.4 Skin metastasis(1) ECACC
IGR-37 Lymph node metastasis (2) DSMZ
Mel-RC08 Brain metastasis DPUV
Human T-cell
Lymphoma
Hut-78 Primary ECACC
List of tested cell lines, tumor type, origin (primary or metastasis) and source.
DSMZ – German Resource Centre for Biological Material, ECACC – European
Collection of Cell Cultures, ATCC - American Type Culture Collection,
DPUV – Department of Pathology, University of Valencia, Valencia, Spain).
(1)Established from the same patient as cell line WM-115.
(2)Established from the same patient as cell line IGR-39.
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Chemokines are chemoattractant cytokines which were
initially characterized by their important role in leukocyte
recruitment during inflammatory and immune responses
[1]. They act through the interaction with a subfamily of
G protein-coupled receptors [2] and the extent of the
cellular response triggered by chemokines depends on the
amount of receptor expressed at the plasma membrane,
which is a consequence of the balance between endocy-
tic and recycling pathways [3]. Several studies have
shown that chemokines and their receptors are involved
in different steps of tumorigenesis, including angiogen-
esis, tumor growth, invasion and metastasis of many
human cancers [4,5].
Chemokines and their receptors are of great importance
in the melanoma tumor progression [6]. The expression
of CXCR4 by melanoma cells in primary lesions is signifi-
cantly associated with the presence of ulceration, in-
creased tumor thickness and higher mortality rate [7]. The
expression of CXCR3 has been observed in patients with
primary invasive cutaneous melanomas and there is a sig-
nificant association of CXCR3-positive tumor cell immu-
nostaining with tumor thickness >1 mm [8].
Cancer metastasis is the complex process by which
primary tumors spread to a distant location and is the
main cause of death for most cancer patients [9]. Che-
mokines and their receptors regulate organ selectivity in
metastasis. They are expressed at specific organs and act
on tumor cells, which express the correspondent recep-
tors, inducing their directed migration. Chemokines also
improve tumor cell proliferation, survival and adhesion
to microvessel walls, helping the process of extravasation
into the target tissue [10,11]. Indeed, it has been shown
that mouse melanoma B16F10 cells constitutively express
CXCR3, and its ligands CXCL9/Mig, CXCL10/IP-10, and
CXCL11/I-TAC induce cellular responses in vitro, such as
actin polymerization, migration, invasion, and cell survival
[12]. Moreover, the expression of several chemokine re-
ceptors has been associated with a greater risk of develop-
ing regional and distant metastases [7,8] as lymph node
metastasis (CCR7 [13]; CCR10, [14]; CXCR3 and CXCR4;
[15]), pulmonary metastasis (CXCR4) or skin metastasis
(CCR10; [13]). The role in melanoma of the recently dis-
covered CXCR7, which binds to CXCL11 and CXCL12
[16] is still not clear. However, it has been shown that
CXCR7 is involved in tumor cell growth, survival, and
metastasis in several tumor types [17].
The aim of this work was to characterize the secretion
and the intracellular expression of the chemokines
CXCL9, CXCL10, CXCL11, CXCL12, CCL19, CCL21,
CCL27 and CCL28 and the surface and intracellular ex-
pression of their chemokine receptors CXCR3, CXCR4,
CXCR7, CCR7 and CCR10 in human melanoma cell
lines, and the effect of xenotransplantation on thechemokine/chemokine receptor expression. We have
included cell lines of primary and metastatic origin, as
differences in chemokine receptors expression have been
reported in uveal melanoma cell lines depending on
their origin [18].
Methods
Cell lines and cell culture conditions
The selected cell lines included cells of primary and meta-
static origin. Thirteen human melanoma cell lines were
used (Table 1), five established from primary tumors and
eight established from metastases at different locations.
Twelve of these cell lines are commercially available and
one (Mel-RC08) was established and characterized in our
laboratory [19]. The Hut-78 cell line was also included in
this study as it was previously reported that it expresses
some of the chemokine receptors studied [20]. All cell
lines were grown in a humidified atmosphere with 5%
CO2 using RPMI 1640 medium, supplemented with 10%
fetal bovine serum inactivated by heat, 2 mM L-glutamine,
100 UI/mL penicillin and 100 μg/mL streptomycin sulfate
(Gibco™, Invitrogen, Carlsbad, CA, USA).
Human tumor xenografts and derived cell lines
The primary WM-115 and the metastatic WM-266.4 cell
lines, established from the same patient, were inoculated
into 4–6 weeks old BALB/c athymic nude mice (Charles
River, Spain). Each mouse was inoculated with 200 μl
containing 2×106 cells, and due to different growth rates
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sacrificed 35 days after inoculation and the ones inocu-
lated with WM-115 were sacrificed 77 days after inocu-
lation. All procedures were performed according to the
institutional recommendations and guidelines for the
good care of laboratory animals, and were approved by
the Research Ethical Committee of the University Clinic
Hospital-INCLIVA, Valencia.
Tumors were extracted and disaggregated using 0.02%
collagenase type II (Sigma-Aldrich, St. Louis, MO, USA).
Cells were resuspended in culture medium and part of
them were immediately used in flow cytometry experi-
ments (hereafter referred as xenografts WM-115-X and
WM-266-X) and some cells were maintained in culture
to establish new cell lines after xenotransplantation. Five
cell lines were obtained from different xenografts of
WM-115 and six cell lines were derived from distinct
xenografts of WM-266.4. These modified cell lines were
named WM-115-CX and WM-266-CX (CX stands for
cultured xenografts).
Immunocyochemistry
Cells were grown in Lab-Tek chamber slides (Miles
Laboratories, Naperville, IL, USA). After washing with
PBS, the cells were fixed with cold methanol-acetone for
5 min. Mouse monoclonal antibodies (mAb) against hu-
man CXCR3, CXCR4, CXCR7, CCR7, CXCL12, CCL19,
CCL27 were from R&D Systems (Minneapolis, MN, USA)
and mouse mAb against human CXCL10 was from BD
Biosciences (Franklin Lakes, NJ, USA). Goat anti-
human CCR10 polyclonal antibody (pAb) was from
Abcam (Cambridge, MA, USA), goat anti-human
CXCL9 and CCL21 pAbs were from R&D Systems and
rabbit anti-human CXCL11 pAb was from Peprotech
(Rocky Hill, NJ, USA). The cells reacted with each of these
primary antibodies for 1 h at room temperature. The at-
tached antibodies were visualized by the avidin-biotin-
peroxidase procedure (Dako, Carpentaria, CA, USA).
Flow cytometry
Antibodies and fluorochromes
All mAbs against chemokine receptors were conjugated
to phycoerytrin (PE). mAbs against CXCR3, CXCR4,
CCR7 and correspondent isotypic controls were pur-
chased from BD Biosciences. mAbs against CXCR7 and
CCR10 and correspondent isotypic controls were pur-
chased from R&D Systems. All chemokine ligands
(CXCL9, CXL10, CXCL11, CXCL12, CCL19, CCL21,
CCL27 and CCL28) were detected using primary mouse-
anti-human mAbs from R&D Systems with a secondary
goat anti-mouse antibody labeled with FITC (R&D
Systems). The DNA intercalating fluorochrome 7-
Aminoactinomycin D (7-AAD, Sigma-Aldrich) was used
for dead cells staining.Cell surface expression of chemokine receptors
Cells at subconfluency (50–70%) were detached with
2 mM EDTA in PBS, washed and resuspended in ice-
cold culture medium at 1×106cells/ml (the suspension
cell line Hut-78 was also resuspended at the same con-
centration). Subsequently, 100 μl of this cell suspension
were incubated on ice for 30 min with the chemokine
receptors mAbs and correspondent isotypic controls.
After incubation, cells were washed with ice-cold PBS
and resuspended in 500 μl of culture medium for flow
cytometric analysis. To determine dead cells 3 μg/ml 7-
ADD were added prior to cytometric analysis. The mean
percentage (%) of cells which expressed chemokine re-
ceptors at the cell surface, as well as the mean fluores-
cence intensity (MFI) calculated as the ratio between the
mean fluorescence of the positive population in the sam-
ples stained with the mAb anti-receptor and the
correspondent isotypic control were determined.
Intracellular expression of chemokine receptors
Cells at subconfluency (50–70%) were detached with
2 mM EDTA in PBS, washed, fixed with 4% paraformalde-
hyde and permeabilized with 0.1% Triton/PBS adjusting
cell suspension to 1×106cells/ml. Then, 100 μl volumes of
this cell suspension were incubated on ice for 30 min with
the chemokine receptors mAb and correspondent isotypic
controls. After incubation, cells were washed with ice-cold
1%BSA/PBS and resuspended in 500 μl of ice-cold 1%BSA/
PBS for flow cytometric analysis. The mean percentage (%)
of cells which expressed chemokines intracellularly, as well
as the MFI calculated as the ratio between the mean fluor-
escence of samples stained with the mAb anti-receptor and
the correspondent isotypic control were determined.
Intracellular chemokine expression
Cells at subconfluency (50–70%) were detached with
2 mM EDTA in PBS, washed, fixed with 4% paraformal-
dehyde and permeabilized with 0.1% Triton/PBS adjust-
ing cell suspension to 1×106cells/ml. Subsequently,
100 μl volumes of this cell suspension were incubated
on ice for 30 min with the chemokine unconjugated
mAbs. Afterwards, cells were washed twice with ice-cold
1%BSA/PBS and incubated on ice for 30 min with the
secondary FITC-conjugated antibody. An aliquot of
100 μl of cell suspension incubated only with the sec-
ondary FITC-conjugated antibody was used as a control
for all the chemokine ligands. Finally, cells were washed
twice and resuspended in 500 μl of ice-cold 1%BSA/PBS
for flow cytometric analysis. The mean percentage (%) of
cells which expressed chemokine receptors intracellu-
larly, as well as the MFI calculated as the ratio between
the mean fluorescence of samples stained with the mAb
anti-receptor and the correspondent isotypic control
were determined.
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kine receptors and the intracellular expression of che-
mokines and their receptors was always performed in
the same day, 24 h after sub-culturing, using cells with
identical culture conditions.
Cytometer settings
All the analyses were performed in a FC500 MCL flow
cytometer (Beckman-Coulter, CA, USA) with an air-
cooled argon ion laser (488 nm, 15 mW). This standard
instrument is equipped with two light scatter detectors
that measure the forward scatter (an estimation of cell
size) and the side scatter (an estimation of intracellular
complexity), and five photomultiplier tubes that detect
the appropriately filtered light. FITC fluorescence was
collected at 525 ± 20 nm, PE at 575 ± 20 nm and 7-AAD
at 675 ± 20 nm. When determining dead cells (for quan-
tification of the cell surface expression of receptors) all
measurements were restricted to live cells by gating the
cells that excluded 7-AAD. In all other cases, the popu-
lation was selected based on forward and side scatter
parameters.
Chemokine secretion
The quantification of chemokine secretion levels was
performed in cell culture medium collected 24 hours
after sub-culturing the cells using the commercial multi-
plex kits MILLIPLEX™ Multi-Analyte Profiling (MAP)
(Millipore, Billerica, MA, USA) according to manufac-
tures indications. Furthermore, as a positive control the
secretion of IL-8 and Gro were also quantified. Cells
were grown in 10 ml of culture medium and after 24 hours
of sub-culturing reached approximately 70% confluency.
The processed samples were subsequently analyzed using
Luminex 100™ System (Luminex Coorporation, Austin,
TX, USA).
Statistical analysis
All measurements in cell lines were made in triplicate.
For flow cytometry experiments, the number of positive
cells stained with the different antibodies was compared
with the number of positive cells in the correspondent
negative controls (isotype or secondary antibody) and
the differences were analyzed using Student’s t-test and
considered significant when p < 0.05. For chemokine se-
cretion experiments, the concentration obtained in each
sample was compared to the lowest standard concentra-
tion of the standard curve and the differences were ana-
lyzed using Student’s t-test, and considered significant
when p < 0.05. The comparison between the expression
of chemokines and their receptors between the original
cell lines WM-115 and WM-266.4 and the tumors
(WM-115-X, WM-266-X) and cell lines (WM-115-CX,
WM-266-CX) obtained after xenotransplantation wasanalyzed using Student’s t-test and considered significant
when p < 0.05.
Results
Surface expression of chemokine receptors CXCR3,
CXCR4, CXCR7, CCR7 and CCR10
We found that melanoma cell lines did not express or
express in a low degree (less than 2% of the population;
Table 2) the chemokine receptors on their cell surface.
The small positive subpopulations were mostly observed
in lines obtained from primary tumors. Representative
flow cytometry plots are shown in Figure 1.
Intracellular expression of chemokine receptors CXCR3,
CXCR4, CXCR7, CCR7 and CCR10 in human melanoma
cell lines
All cell lines significantly expressed all chemokine recep-
tors intracellularly (Table 3). However, variability was
found in the pattern of expression depending on the cell
line and receptor studied. Representative histograms are
shown in Figure 2A and B. Furthermore, the level of
protein expression varied between receptors and cell
lines. In general, CXCR4 seems to be the most expressed
receptor, with higher MFI values, while CCR7 appears to
be the receptor which is expressed at lowest levels, hav-
ing lower MFI values (Table 3).
Intracellular expression of chemokines CXCL9, CXCL10,
CXCL11, CXCL12, CCL19, CCL21, CCL27 and CCL28 in
human melanoma cell lines
Most chemokines were expressed intracellularly in all
melanoma cell lines (CXCL9, CXCL11, CXCL12, CCL19,
CCL21 and CCL27). The chemokines exhibiting lower
levels of intracellular expression were CXCL10 and
CCL28 (Table 4). Representative histograms are shown in
Figure 3A and B. The control Hut-78 cell line only
expressed CXCL9, CCL19 and CCL27 significantly, and at
lower levels than the melanoma cell lines.
Secretion of chemokines CXCL9, CXCL10, CXCL11,
CXCL12, CCL19, CCL21, CCL27 and CCL28 in human
melanoma cell lines
CXCL10 was the only chemokine secreted in the studied
melanoma cell lines. This chemokine was secreted in
low concentrations by A375 and SK-Mel2 (40 pg/ml and
38 pg/ml, respectively). All melanoma cell lines secreted
the control chemokines IL-8 and Gro (although at different
amounts, Table 5).
Immunocytochemistry
An immunocytochemical analysis of the cell lines was
performed to check the intracellular presence of the che-
mokine receptors and chemokines (with the exception
of CCL28). The results confirm the results obtained by
Table 2 Surface expression of chemokine receptors
Origin Cell line CXCR3 CXCR4 CXCR7 CCR7 CCR10
% MFI % MFI % MFI % MFI % MFI
P IPC-298 0.16 3.10 ns - ns - ns - 0.23 11.37
P Mel-Juso ns - ns - 0.43 27.70 ns - 0.43 12.74
P Mel-HO 0.07 4.83 ns - 0.36 4.91 ns - ns -
P IGR-39 0.83 8.31 ns - 1.59 7.09 ns - 1.79 4.05
P WM-115 0.15 5.91 ns - ns - ns - 0.11 5.09
M A-375 ns - ns - ns - ns - ns -
M MeWo ns - ns - ns - ns - ns -
M SK-Mel28 ns - ns - ns - ns - ns -
M Malme-3 M ns - ns - ns - ns - ns -
M SK-Mel 2 0.44 3.16 ns - 0.35 10.34 ns - 0.35 3.84
M WM-266-4 ns - ns - ns - ns - ns -
M IGR-37 0.13 3.47 ns - 0.22 14.76 ns - ns -
M Mel-RC08 ns - ns - ns - ns - ns -
P Hut-78 63.07 3.37 5.90 6.91 ns - 3.36 7.66 1.23 8.36
For each cell line (Origin; P: primary tumor, M: metastasis) mean percentage (%) and mean fluorescence index (MFI; calculated as the ratio between the mean
fluorescence of the positive population in the samples stained with the mAb anti-receptor and their correspondent isotypic control) of cells which significantly
expressed (p < 0.05) chemokine receptors at the cell surface are shown (ns: not significant expression).
WM-115
0% CXCR4+
Hut-78
63% CXCR3+
IGR-39
1.6% CXCR7
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un
ts
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PE Log
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A B
C D
Figure 1 Surface expression of chemokine receptors. Representative examples for the quantification of chemokine receptors surface
expression by flow cytometry are shown. Overlaid histograms of PE fluorescence of specific anti-receptor monoclonal antibody (continuous red
line) and correspondent isotypic control (discontinuous black line) show the control Hut-78 cell line with a high percentage of CXCR3+ cells (A),
WM-115 with no expression of CXCR4 (B) and IGR-39 with a small subpopulation of CXCR7+ cells (C), which is further illustrated in a biparametric
dotplot of FS vs PE fluorescence (D).
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Table 3 Intracellular expression of chemokine receptors
Origin Cell line CXCR3 CXCR4 CXCR7 CCR7 CCR10
% MFI % MFI % MFI % MFI % MFI
P IPC-298 99.45 7.34 99.41 6.29 21.26 1.48 58.30 1.92 45.67 1.86
P Mel-Juso 53.74 3.27 62.50 4.16 3.58 1.18 39.58 2.51 18.64 1.78
P Mel-HO 96.71 5.28 98.99 7.82 53.07 2.21 82.49 3.13 56.36 2.26
P IGR-39 95.73 3.73 95.76 4.04 81.82 2.59 87.87 2.43 37.51 1.70
P WM-115 88.59 5.40 92.45 3.95 4.97 1.57 20.16 1.70 13.67 1.57
M A-375 43.61 2.51 94.44 14.10 63.20 3.45 12.70 1.59 45.45 2.89
M MeWo 25.02 2.21 80.60 5.98 80.65 6.59 2.58 1.32 61.27 3.53
M SK-Mel28 56.56 2.43 93.22 8.63 73.86 5.02 1.20 1.20 65.81 2.59
M Malme-3 M 64.99 2.07 92.84 2.66 97.78 5.66 64.86 1.99 71.88 2.37
M SK-Mel 2 96.43 6.92 98.33 15.73 33.52 2.04 78.23 2.08 96.34 4.68
M WM-266-4 74.08 2.22 96.26 3.39 21.53 1.68 40.16 1.69 24.00 1.63
M IGR-37 97.88 4.25 97.85 4.53 43.84 1.89 67.83 2.03 56.29 1.89
M Mel-RC08 45.79 2.69 95.02 7.33 72.05 3.99 9.14 1.61 60.81 2.84
P Hut-78 82.05 2.93 95.95 4.62 19.75 1.95 13.53 1.68 88.40 4.08
For each cell line (Origin; P: primary tumor, M: metastasis) mean percentage (%) and mean fluorescence index (MFI; calculated as the ratio between the mean
fluorescence of the samples stained with the mAb anti-receptor and their correspondent isotypic control) of cells which significantly expressed (p < 0.05)
chemokine receptors intracellularly are shown (ns: not significant expression).
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mokines, with the exception of CCL10. Some represen-
tative examples are shown in Figure 2 (C and D) and
Figure 3 (C and D).
Surface and intracellular expression of chemokines and
their receptors in WM-115 and WM-266.4 cell lines after
xenotransplantation
Tumors obtained from the xenotransplanted WM-266.4
cell line grew faster than those obtained from the WM-
115 cell line. The growth of the former was noticed after
10 days of inoculation while the growth of the latter was
noticed after 30 days of inoculation. After tumor disag-
gregation, a subset of cells was used directly for quantifi-
cation of the expression of chemokines and their
receptors by flow cytometry and another subset was cul-
tured for a few passages for posterior quantification, in
order to compare them with the original cell lines.
When cultured, the cells exhibited some variability in
the morphology and were slightly different from the ori-
ginal cell lines.
Surface expression of chemokine receptors
When compared with the original cell lines, the WM-
115-X and WM-266-X tumors obtained after xenotrans-
plantation, as well as the cell lines derived from them
(WM-115-CX and WM-266-CX) had similar patterns of
cell surface expression of receptors, that is, minute or no
expression was observed, without significant differences
with the original cell lines.Intracellular expression of chemokine receptors
When compared with the original cell line, the WM-
115-X xenografts, as well as the derived WM-115-CX
cell lines, showed a substantial increase in the expression
of CCR7 and CCR10, a considerable decrease in the ex-
pression of CXCR4 and a slight but significant decrease
in the expression of CXCR3. CXCR7 showed an in-
creased expression in the WM-115-X xenografts that
was not observed in the derived WM-115-CX cell lines
that were not significantly different from the original cell
line (Table 6, Figure 4A). WM-266-X xenografts showed
a significant decrease of CXCR4 and significant increases
of CXCR7 and CCR7, when compared with the original
cell line, while the WM-266-CX derived cell lines pre-
sented increases of CXCR3, CCR7 and CCR10 with re-
spect to the original cell line (Table 6, Figure 4B).
Intracellular expression of chemokines
In WM-115-X xenografts a general decrease of chemo-
kine expression is observed to levels similar to negative
controls for most of the studied chemokines with re-
spect to the initial WM-115 cell line, as can be detected
by mean fluorescence index (Table 7). In WM-115-CX
lines derived after xenotransplantation an increased ex-
pression of all chemokines is observed, when compared
with the original cell line (Table 7, Figure 5A). In WM-
266-X xenografts, a general decrease of chemokine
expression is also observed when compared with WM-
266.4 cell line, but that does not reach negative control
values. The WM-266-CX cell lines derived from the
A
WM-115
CXCR4+
MFI=3.95
B
WM-266.4
CCR10+
MFI=1.63
Co
un
ts
PE Log
C D
Intracellular Expression - Receptors 
100100 µ µ
Figure 2 Intracellular expression of chemokine receptors. Representative examples for the quantification of intracellular chemokine receptor
expression by both flow cytometry (A, B) and immunocytochemistry (C, D) are shown. Mean fluorescence indexes and overlaid histograms of PE
fluorescence of specific anti-receptor monoclonal antibody (continuous red line) and correspondent isotypic control (discontinuous black line) are
shown for CXCR4 in the WM-115 cell line (A) and for CCR10 in the WM-266.4 cell line (B). Corresponding immunocytochemical staining of CXCR4
in WM-115 (C) and CCR10 in WM-266.4 (D).
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CXCL12 and CCL19 (Table 7, Figure 5B) with respect to
the original cell line.
Discussion
It has been previously demonstrated that chemokine
receptors allow the directed migration towards specific
organs [21]. Moreover, the receptors CXCR3, CXCR4,
CCR7 and CCR10 have been implicated in the process
of metastasis in melanoma, based on studies with ani-
mals [12,13]. Some of them, namely CXCR4, were also
associated with metastasis in other types of neoplasms
like breast, prostate, ovarian, colon and lung cancers
[21]. CXCR7 is a chemokine receptor that shares ligands
CXCL11 and CXCL12 with CXCR3 and CXCR4, re-
spectively and that has recently been found to mediate
CXCL12-induced migration in normal human epidermal
melanocytes [22].Most studies that analyze these chemokine receptors
at the protein level in melanomas have been performed
using mainly immunohistochemistry and western blot-
ting techniques, which do not permit the correct evalu-
ation of cell surface expression. Gene expression studies
at the mRNA level have shown that human melanoma
cell lines express CXCR4 and also receptors CCR10 and
CCR7 which could be implicated in the frequent metas-
tasis of melanoma to skin and lymph nodes, respectively
[21]. However, these studies do not imply either the
presence of functional receptors at the cell surface. On
the other hand, few studies have determined the produc-
tion by human melanoma cells of the chemokines that
interact with these receptors. Using immunohistochemi-
cal techniques, a correlation has been found between T
immunoreactive cells and the expression of CCR10 and
its ligand CCL27 in cutaneous melanocytic lesions [14].
Expression of both receptor and chemokine was found
Table 4 Intracellular expression of chemokine ligands
Origin Cell line CXCL9 CXCL10 CXCL11 CXCL12 CCL19 CCL21 CCL27 CCL28
% MFI % MFI % MFI % MFI % MFI % MFI % MFI % MFI
P IPC-298 95.39 3.69 0.93 1.11 7.00 1.36 97.93 5.34 99.02 16.86 53.98 1.94 98.71 7.39 ns ns
P Mel-Juso 93.22 10.88 ns ns 12.90 2.10 89.57 5.80 99.04 70.62 6.12 1.60 98.75 17.36 ns ns
P Mel-HO 96.59 8.39 7.32 1.32 65.87 5.83 97.86 8.12 98.62 60.07 82.62 3.72 98.65 23.48 ns ns
P IGR-39 14.05 1.52 ns ns 10.49 1.37 95.86 3.89 98.76 16.71 23.50 1.54 98.58 5.21 ns ns
P WM-115 28.31 2.06 0.46 1.12 2.66 1.24 81.77 3.96 98.79 20.00 15.55 1.65 94.06 4.89 ns ns
M A-375 84.56 6.18 0.42 1.07 88.71 7.46 10.89 1.67 92.34 71.31 32.60 3.42 89.92 25.21 1.14 1.29
M MeWo 45.53 5.28 1.46 1.44 46.10 8.72 24.41 2.15 50.06 34.71 23.62 3.96 37.85 10.86 1.74 1.86
M SK-Mel28 67.63 3.06 2.01 1.18 82.59 5.72 71.82 3.09 86.62 44.41 28.42 1.96 86.34 14.37 ns ns
M Malme-3 M 50.32 3.45 ns ns 71.62 3.45 77.48 3.37 98.02 34.57 5.45 1.70 97.90 11.06 ns ns
M SK-Mel 2 81.72 3.18 ns ns 94.63 5.53 95.94 8.46 98.34 36.70 22.45 1.86 97.47 13.02 ns ns
M WM-266-4 71.84 4.57 15.19 1.74 46.26 3.24 98.24 9.56 98.58 30.17 60.21 3.71 98.50 11.38 1.14 1.25
M IGR-37 87.92 5.06 ns ns 36.32 1.88 92.76 3.78 98.83 47.66 38.71 2.44 98.96 21.35 ns ns
M Mel-RC08 49.96 3.29 ns ns 80.84 6.87 16.64 1.68 86.38 55.25 22.94 2.19 82.77 15.33 1.56 1.22
P Hut-78 1.90 1.69 ns ns ns ns ns ns 65.99 11.71 ns ns 39.11 3.81 ns ns
For each cell line (Origin; P: primary tumor, M: metastasis) mean percentage (%) and mean fluorescence index (MFI; calculated as the ratio between the mean
fluorescence of the samples stained with the mAb anti-receptor and their correspondent isotypic control) of cells which significantly expressed (p < 0.05)
chemokine ligands intracellularly are shown (ns: not significant expression).
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http://www.biomedcentral.com/1471-2407/14/118in human melanoma cells. Their results suggest that in
human melanomas CCR10 and CCL27 may act on the
ability of neoplastic cells to grow, invade tissue, dissem-
inate to lymph nodes and to escape the host immune
response. Recently, immunohistochemical expression of
CXCR4, CCR7 and CCR10 and their ligands has been
described in tumor cells from primary and metastatic
melanomas. The CXCL12-CXCR4 and CCL27-CCR10
ratios quantified by real time RT-PCR were found to be
significantly higher in thin than in thick primary mela-
nomas, and inversely associated with the development of
distant metastasis [23]. Although these studies demon-
strate the production of chemokines by the tumor cells
they do not necessarily indicate their secretion from the
cell. In this study we have determined the surface and
intracellular expression of chemokine receptors, as well
as the intracellular chemokine expression using flow cy-
tometry and the chemokine secretion to the extracellular
medium using commercial multiplex kits, to ascertain
the extracellular chemokine-ligand interaction in human
melanoma cell lines. Flow cytometry is one of the methods
available for immunophenotyping (i.e. cellular phenotyp-
ing using antibodies) which allows working with live cells
and, therefore, to analyze cell surface expression of pro-
teins like receptors [24].
We have evaluated, using flow cytometry, the expres-
sion of the chemokine receptors CXCR4, CXCR3,
CXCR7, CCR7 and CCR10, at cell surface and intracellu-
lar levels, for thirteen human melanoma cell lines. We
detected surface expression of CXCR3 in the cell linesIPC-298, MEL-HO, IGR39, WM-115, SK-Mel 2, and
IGR-37, surface expression of CXCR7 in the cell lines
Mel-Juso, MEL-HO, IGR-39, SK-Mel 2, and IGR-37, and
surface expression of CCR10 in the cell lines IPC-298,
Mel-Juso, IGR-39, WM-115 and SK-Mel2. However, in
all cases this expression was only detected in a small
subpopulation of cells (less than 2%). Our results differ
from a study that describes functional plasma membrane
CXCR4 in the cell lines MeWo and A375 [15].
All cell lines significantly expressed all the receptors
intracellularly, although there was significant variability
in the pattern of expression between the different cell
lines. The intracellular expression of chemokine recep-
tors, in other tumors, has been shown to be correlated
with metastasis directed to lymph nodes and with a bad
prognosis (e.g., CXCR4 in breast cancer [25]; in lung
cancer [26]; in colon cancer [27]). In the case of hepato-
cellular carcinoma the intracellular expression of CXCR4
with lack of its expression at the cell surface and lack of
response to its ligand CXCL12 has been reported [28].
In normal cells, CXCR7 protein expression in human
differentiated neurons is mostly limited to the intracellular
compartment with little to no expression on the plasma
membrane [29]. In the case of multipotent mesenchymal
stem cells (MSC) intracellular expression, at protein level,
of chemokine receptors CCR1, CCR3, CXCR3, CXCR4
and CXCR6 has been found [30]. However, the surface
expression of these chemokine receptors was much more
restricted with only one of the chemokine receptors
(CXCR6) displaying a strong signal.
C D
A
WM-115
CXCL12+
MFI=3.96
B
WM-266.4
CCL27+
MFI=11.38
Co
un
ts
FITC Log
Intracellular Expression – Chemokines Ligands 
100100 µ µ
Figure 3 Intracellular expression of chemokines. Representative examples for the quantification of intracellular chemokine expression by both
flow cytometry (A, B) and immunocytochemistry (C, D) are shown. Mean fluorescence indexes and overlaid histograms of PE fluorescence of
specific anti-receptor monoclonal antibody (continuous red line) and correspondent isotypic control (discontinuous black line) are shown for
CXCL12 in the WM-115 cell line (A) and for CCL27 in the WM-266.4 cell line (B). Corresponding immunocytochemical staining of CXCL12 in
WM-115 (C) and CCL27 in WM-266.4 (D).
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http://www.biomedcentral.com/1471-2407/14/118A major feature of solid tumor microenvironment is
hypoxia, i.e. decreased availability of oxygen [31]. In-
deed, there are studies which show an increase of che-
mokine receptor expression in hypoxic conditions. For
example, an increase in CXCR4 surface expression in
the two human breast cancer cell lines, MDA-MB-231
and MCF7, following exposure to hypoxia resulted in
a significant increase in migration and invasion in re-
sponse to SDF1-alpha in vitro [32]. However, after sub-
mitting the primary cell lines WM-115 and IGR-39,
and the metastatic cell lines WM-266.4 and IGR-37 to
hypoxic conditions, we still failed to find an increase in
cell surface expression of the chemokine receptors
studied (results not shown).
Chemokine receptors form part of the family of G-
protein coupled receptors. The appropriate delivery of
chemokine receptors to the cell surface to allow receptor -
ligand interactions, and their subsequent retrieval from
the plasma membrane are of fundamental importance
for the regulation of their activity [3,33]. Both duringand subsequent to synthesis, chemokine receptors undergo
a process of maturation before reaching the cell membrane.
They must be properly inserted into the cell membrane,
achieve their correct folding while still resident at the
endoplasmic reticulum, traverse from the cis- to the
trans-Golgi while undergoing modification, and finally
be targeted to the plasma membrane where they attain
residence as mature proteins. In order for a chemokine
receptor to transduce an extracellular signal it must
both traffic to and be retained at the cellular surface to
allow for receptor- ligand interaction. Multiple proteins
not involved in the signal transduction cascade have
been identified which stabilize receptor surface expres-
sion [34]. Post-translational modifications can also alter
surface expression of the receptor. In neuroblastoma,
CXCR4 surface expression requires ubiquination and
oligomerization of the receptor [35]. Finally, factors in-
volved in the endocytic and recycling pathways could
also affect the amount of receptor expressed at the
plasma membrane [3]. For instance, CCR7 recycling to
Table 5 Secretion of chemokines
Origin Cell line GRO IL-8 CXCL10
P IPC-298 936 821 §
P Mel-Juso 3939 6663 §
P Mel-HO 439 274 §
P IGR-39 117 787 §
P WM-115 341 7614 §
M A-375 4091 5234 40
M MeWo 1234 235 §
M SK-Mel28 197 212 §
M Malme-3 M 217 43 §
M Sk-Mel2 1956 7457 38
M WM-266-4 6419 346 §
M IGR-37 2740 117 §
M Mel-RC08 1921 4296 §
P Hut-78 § § 550
For each cell line (Origin; P: primary tumor, M: metastasis) the mean
concentration (pg/ml) of secreted chemokines is shown (§ concentration
below the lower limit of detection).
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http://www.biomedcentral.com/1471-2407/14/118the cell surface has been found to be dependent on ubi-
quitination of the receptor [36].
In this work we have also quantified by flow cytometry
the intracellular protein expression of the chemokines which
activate each of the receptors studied: CXCL9, CXCL10
(CXCR3), CXCL11 (CXCR3 and CXCR7), CXCL12 (CXCR4
and CXCR7), CCL19, CCL21 (CCR7) and CCL27, CCL28
(CCR10). We found a certain pattern in their expression.
Most chemokines were expressed in all cell lines. However,
chemokines CXCL10 and CCL28 had a low or null expres-
sion in most of the cell lines (Table 4).
We also analyzed the secretion of chemokines in the
culture medium of all cell lines. From all the chemo-
kines studied, the only chemokine secreted by the mel-
anoma cell lines was CXCL10. This chemokine was
secreted in low concentrations by A375 and SK-Mel-2.
As a positive control we also quantified the secretion ofTable 6 Intracellular expression of chemokine receptors after
CXCR3 CXCR4
% MFI % MFI
WM-115 88.59 5.40 92.45 3.95
WM-115-X 59.84 3.46 14.10 1.62 5
WM-115-CX 76.11 3.95 12.14 1.65
WM-266 74.08 2.22 96.26 3.39 2
WM-266-X 28.19 2.24 6.71 1.26 1
WM-266-CX 91.65 4.41 94.17 3.74 5
Mean percentage (%) and Mean fluorescence index (MFI; calculated as the ratio bet
and correspondent isotypic control) of cells which significantly expressed (p < 0.05)
values of the original cell lines; WM-115-X and WM-266-X represent the mean value
values of the different cell lines obtained after culturing the xenografts.the IL-8 and Gro chemokines that are produced by
human melanoma [37].
There is evidence, based on experiments designed to
avoid HIV-1 infection [38,39], that expression of genetic-
ally modified chemokines (intrakines) with an added
endoplasmic reticulum retention signal are able to avoid
surface expression of their chemokine receptors, by
interacting with the nascent chemokine receptors and
retaining them in the endoplasmic reticulum. This pro-
cedure has been extended to other chemokine receptors
not involved in HIV infection [40,41]. The transfection
with the native chemokine without the endoplasmic re-
tention signal also inhibited viral entry as demonstrated
by the inhibitory effects on the syncytium formation
[38], suggesting that the native chemokine can also pre-
vent the transport of the receptor to the cell surface.
This early interaction of chemokines with their chemo-
kine receptors could alter post-translational processes,
like glycosylations [42], or interactions with escort pro-
teins that have been found necessary for trafficking to
the plasma membrane and for expression of the proteins
on the cell surface in other members of the family of G-
protein-coupled receptors to which chemokine receptors
belong [43,44], therefore resulting in intracellular accu-
mulation of chemokine receptors and interacting che-
mokines. Interestingly, the only chemokine that was
found to be secreted in two cell lines in our study,
CXCL10, shows a minimal or no intracellular expression
in the melanoma cell lines a fact that could reflect that it
does not interact intracellularly with its receptor and
therefore is not accumulated within the cell.
Tumor microenvironment originates in the interactions
between malignant and non-transformed cells. Intercellu-
lar communication is driven by a complex network of
cytokines, chemokines, growth factors, and inflammatory
and matrix enzymes [45]. Chemokines and their receptors
are important in cancer for cell trafficking into and out of
the tumor microenvironment, and chemokines made by
malignant and stromal cells contribute to the tumor-xenotransplantation
CXCR7 CCR7 CCR10
% MFI % MFI % MFI
4.97 1.57 20.16 1.70 13.67 1.57
8.89 4.14 75.32 4.10 66.90 3.47
5.44 1.34 82.03 3.44 81.90 3.44
1.53 1.68 40.16 1.69 24.00 1.63
3.96 2.08 56.31 2.50 28.54 1.83
3.67 2.34 72.95 2.48 88.62 4.60
ween the mean fluorescence of samples stained with the mAb anti-receptor
chemokine receptors intracellularly. WM-115 and WM-266 represent the mean
s of the different xenografts; WM-115-CX and WM-266-CX represent the mean
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Figure 4 Intracellular expression of chemokine receptors in WM-115 and WM-266.4 cell lines after xenotransplantation. Comparison
between mean fluorescence index (MIF, ± standard error) values of intracellular chemokine receptors in the original melanoma cell lines WM-115
(A) and WM-266.4 (B) and the tumors and cell lines obtained after xenotransplantation.
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http://www.biomedcentral.com/1471-2407/14/118associated leukocyte component, to angiogenesis and to
the generation of fibroblast stroma. Changes in the tumor
microenvironment such as hypoxia, as we mentioned pre-
viously, or different molecular factors can alter the expres-
sion of chemokines and their receptors in the malignant
cells [46]. In order to provide an in vivo environment and
stimuli to these established melanoma cell lines we xeno-
grafted the primary cell line WM-115 and the metastaticTable 7 Intracellular chemokine expression after xenotranspl
CXCL9 CXCL10 CXCL11 CXCL1
% MFI % MFI % MFI %
WM-115 28.31 2.06 0.46 1.12 2.66 1.24 81.77 3
WM-115-X ns 1.10 ns 0.90 ns 0.96 0.30 0
WM-115-CX 50.39 5.36 4.33 2.54 15.24 5.25 79.83 5
WM-266 71.84 4.57 15.19 1.74 46.26 3.24 98.24 9
WM-266-X 2.12 1.46 2.53 1.28 22.73 1.93 3.81 1
WM-266-CX 67.84 7.02 3.72 1.41 37.75 4.98 95.52 1
Mean percentage (%) and mean fluorescence index (MFI; calculated as the ratio be
and correspondent isotypic control) of cells which significantly expressed (p < 0.05)
values of the original cell lines; WM-115-X and WM-266-X represent the mean value
values of the different cell lines obtained after culturing the xenografts.cell line WM-266.4 that were initially derived from the
same patient [47], into nude mice. We obtained five differ-
ent tumors from the primary cell line and six different tu-
mors from the metastatic cell line (named WM-115-X
and WM-266-X, respectively). Cells obtained from colla-
genase treatment of these tumors were analyzed directly
by flow cytometry. There were no significant changes in
expression of receptors at the cell surface, although itantation
2 CCL19 CCL21 CCL27 CCL28
MFI % MFI % MFI % MFI % MFI
.96 98.79 20.00 15.55 1.65 94.06 4.89 ns 0.94
.94 50.38 3.80 ns 1.05 22.39 1.62 ns 0.97
.08 98.64 36.76 14.46 4.24 98.17 13.36 3.51 2.98
.56 98.58 30.17 60.21 3.71 98.50 11.38 1.14 1.25
.42 81.95 10.43 2.38 1.33 54.41 3.39 1.25 1.19
4.66 98.10 43.82 50.06 4.00 97.12 12.36 0.29 0.97
tween the mean fluorescence of samples stained with the mAb anti-receptor
chemokine ligands intracellularly. WM-115 and WM-266 represent the mean
s of the different xenografts; WM-115-CX and WM-266-CX represent the mean
BA
Figure 5 Intracellular expression of chemokines in WM-115 and WM-266.4 cell lines after xenotransplantation. Comparison between
mean fluorescence index (MIF, ± standard error) values of intracellular chemokines in the original melanoma cell lines WM-115 (A) and WM-266.4
(B) and the tumors and cell lines obtained after xenotransplantation.
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http://www.biomedcentral.com/1471-2407/14/118must be considered that the disaggregation procedure
could influence the detection of the receptors at this level,
as in the case of the cell lines these were detached solely
using EDTA to avoid the effect of trypsin on the surface
cell receptors. Intracellular receptor and chemokine con-
tent varies in the xenograft with respect to the original cell
line. In WM-115-X there is a significant reduction of
CXCR3 and CXCR4, and a significant increase of CXCR7,
CCR7 and CCR10, while in WM-266-X there is a signifi-
cant decrease of CXCR4 and modest but significant in-
creases in CCR7 and CCR10. The cell lines derived from
the xenografts showed dynamic variations in the expres-
sion of intracellular chemokines and chemokine receptors
when compared with the original cell lines. The changes
in protein expression were different in the primary cell
line with respect to the metastatic cell line. WM-115-CX
showed a decreased expression of CXCR4 and CXCR3together with an increased expression of CCR7 and
CCR10, while WM-266-CX had an increased expression
of CXCR3, CCR7 and CCR10 (Figure 4). However, cell
surface expression of these receptors remained very low
or inexistent in both cases. WM-115-CX showed a higher
intracellular expression of all the tested chemokines, while
WM-266-CX showed intracellular chemokine values that
were similar to the original cell line, with the exception of
CCL12 and CCL19 that show an increase (Figure 5).
A comparative analysis of global gene expression has
been performed between human melanoma cell lines with
different metastatic capacity and the xenografts obtained
by their subcutaneous injection into immunocomprom-
ised mice [48], demonstrating extensive differential ex-
pression between both models. These variations can be
due to selection of determined subpopulations with differ-
ent tumorigenic capacity or to the effect of the different
Pinto et al. BMC Cancer 2014, 14:118 Page 13 of 14
http://www.biomedcentral.com/1471-2407/14/118microenvironment within the nude mouse. Melanoma is a
highly heterogeneous tumor that shows a high degree of
plasticity. Recent evidence indicates that WM-266.4 xeno-
grafts contain a cell subpopulation expressing ABCB5
endowed with intrinsic chemoresistance [49]. ABCB5 has
been described as a marker for tumor-initiating cells in
human melanoma [50]. Although the nature and fre-
quency of cancer stem cells in melanoma is controversial,
it is likely that this model can be applied to human melan-
oma, and different surface markers have been proposed to
define melanoma cell with tumor initiating capacity [51].
Studies performed on melanoma cells growing as melano-
spheres isolated selectively from attached cell lines, het-
erogeneously expressing different stem cell markers, more
efficiently form tumors in immunocompromised mice
than cell line [52], suggesting that various subpopulations
can participate in the formation of the tumor. In our study
a selection process seems to take place within the tumoral
population in the xenograft, especially in the case of WM-
115 derived from a primary tumor where the changes ob-
served in the intracellular chemokine receptors that have
been involved in tumoral growth and progression are
maintained in the derived cell lines in culture medium.
However, intracellular chemokine levels show a general
decrease in the xenografts, being more pronounced in
WM-115-X than in WM-266-X and that seems to be due
to environmental causes, as these changes are not main-
tained in the derived cell lines.Conclusions
In conclusion, we find coexpression of chemokine recep-
tors and their ligands in human melanoma cell lines.
However, this expression is intracellular and receptors are
not found at the cell membrane nor chemokines are se-
creted to the cell medium. The levels of intracellularly
expressed chemokine receptors and their ligands show
dynamic variations after xenotransplantation that differ
depending on the origin of the cell line. These changes
could affect cell trafficking assays that correlate in vitro
and in vivo data. These results could also have implica-
tions in the studies that analyze chemokines or chemokine
receptors expression in melanomas that do not ascertain
the cell membrane location of chemokine receptors or the
secretion of chemokines to the extracellular medium.Competing interests
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